Target Information

Target General Information

Top

Target ID

T22118 (Former ID: TTDS00011)

Target Name

Dopamine D1 receptor (D1R)

Synonyms

D(1A) dopamine receptor

Click to Show/Hide

Gene Name

DRD1

Target Type

Successful target

[1]

Disease

[+] 4 Target-related Diseases

Abortion [ICD-11: JA00]

Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z]

Hypertension [ICD-11: BA00-BA04]

Parkinsonism [ICD-11: 8A00]

Function

Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Click to Show/Hide

BioChemical Class

GPCR rhodopsin

UniProt ID

DRD1_HUMAN

Sequence

MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTN
FFVISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVD
RYWAISSPFRYERKMTPKAAFILISVAWTLSVLISFIPVQLSWHKAKPTSPSDGNATSLA
ETIDNCDSSLSRTYAISSSVISFYIPVAIMIVTYTRIYRIAQKQIRRIAALERAAVHAKN
CQTTTGNGKPVECSQPESSFKMSFKRETKVLKTLSVIMGVFVCCWLPFFILNCILPFCGS
GETQPFCIDSNTFDVFVWFGWANSSLNPIIYAFNADFRKAFSTLLGCYRLCPATNNAIET
VSINNNGAAMFSSHHEPRGSISKECNLVYLIPHAVGSSEDLKKEEAAGIARPLEKLSPAL
SVILDYDTDVSLEKIQPITQNGQHPT

Click to Show/Hide

3D Structure

Click to Show 3D Structure of This Target

PDB

ADReCS ID

BADD_A00129 ; BADD_A01381 ; BADD_A03311 ; BADD_A04234 ; BADD_A05088

HIT2.0 ID

T28IL8

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 4 Approved Drugs

Fenoldopam

Drug Info

Approved

Hypertension

[2], [3]

Methylergonovine

Drug Info

Approved

Spontaneous abortion

[4]

Pergolide

Drug Info

Approved

Parkinson disease

[5], [6]

Phenyltoloxamine

Drug Info

Approved

Allergy

[4]

Clinical Trial Drug(s)

[+] 5 Clinical Trial Drugs

Ecopipam

Drug Info

Phase 3

Cocaine addiction

[7], [8]

Zicronapine

Drug Info

Phase 3

Schizophrenia

[9]

DAS-431

Drug Info

Phase 2

Dementia

[10]

Dihydrexidine

Drug Info

Phase 1/2

Psychotic disorder

[11]

Lu AF28996

Drug Info

Phase 1

Parkinson disease

[12]

Discontinued Drug(s)

[+] 19 Discontinued Drugs

ADROGOLIDE HYDROCHLORIDE

Drug Info

Discontinued in Phase 2

Cognitive impairment

[13]

ADX-10061

Drug Info

Discontinued in Phase 2

Psychotic disorder

[14]

BAM-1110

Drug Info

Discontinued in Phase 2

Parkinson disease

[15]

CY-208243

Drug Info

Discontinued in Phase 2

Pain

[16]

ZELANDOPAM HYDROCHLORIDE

Drug Info

Discontinued in Phase 2

Hypertension

[17]

Berupipam

Drug Info

Discontinued in Phase 1

Psychotic disorder

[18]

BTS-73947

Drug Info

Discontinued in Phase 1

Psychotic disorder

[19]

Odapipam

Drug Info

Discontinued in Phase 1

Psychotic disorder

[20]

SDZ-GLC-756

Drug Info

Discontinued in Phase 1

Glaucoma/ocular hypertension

[21]

A 77636

Drug Info

Terminated

Parkinson disease

[23]

A-68930

Drug Info

Terminated

Hypertension

[24], [25]

A-69024

Drug Info

Terminated

Psychotic disorder

[26]

BIMG80

Drug Info

Terminated

Psychotic disorder

[27]

CEE-03-320

Drug Info

Terminated

Substance use disorder

[28]

NNC-22-0031

Drug Info

Terminated

Psychotic disorder

[29]

Org-10490

Drug Info

Terminated

Psychotic disorder

[30]

SDZ-PSD-958

Drug Info

Terminated

Psychiatric disorder

[31]

SKF 38393

Drug Info

Terminated

Type-2 diabetes

[32], [33]

SKF-81297

Drug Info

Terminated

Parkinson disease

[34], [35]

Preclinical Drug(s)

[+] 1 Preclinical Drugs

BSF-78438

Drug Info

Preclinical

Schizophrenia

[22]

Mode of Action

[+] 6 Modes of Action

Agonist

[+] 8 Agonist drugs

Fenoldopam

Drug Info

[1]

DAS-431

Drug Info

[41]

ADROGOLIDE HYDROCHLORIDE

Drug Info

[4], [41]

CY-208243

Drug Info

[46], [47]

(+)-ADTN

Drug Info

[62]

N-propylnorapomorphine

Drug Info

[62]

SKF-75670

Drug Info

[97]

SKF-83959

Drug Info

[98]

Antagonist

[+] 9 Antagonist drugs

Methylergonovine

Drug Info

[36]

ADX-10061

Drug Info

[44]

ZELANDOPAM HYDROCHLORIDE

Drug Info

[4], [48]

Berupipam

Drug Info

[49]

BTS-73947

Drug Info

[4], [50]

Odapipam

Drug Info

[51]

SCH-23390

Drug Info

[94]

SKF-83556

Drug Info

[62]

[125I]SCH23982

Drug Info

[101]

Modulator

[+] 15 Modulator drugs

Pergolide

Drug Info

[37]

Ecopipam

Drug Info

[39]

Zicronapine

Drug Info

[40]

BAM-1110

Drug Info

[45]

SDZ-GLC-756

Drug Info

[52]

A 77636

Drug Info

[53]

A-68930

Drug Info

[54], [55]

A-69024

Drug Info

[56]

BIMG80

Drug Info

[57]

CEE-03-320

Drug Info

[58]

NNC-22-0031

Drug Info

[29]

Org-10490

Drug Info

[37]

SDZ-PSD-958

Drug Info

[59]

SKF 38393

Drug Info

[33]

SKF-81297

Drug Info

[60]

Inhibitor

[+] 79 Inhibitor drugs

Phenyltoloxamine

Drug Info

[38]

Dihydrexidine

Drug Info

[42]

(+)-(1R,1'S)-berbamunine hydrochloride

Drug Info

[61]

(+)-(1R,1'S)-thaligrisine hydrochloride

Drug Info

[61]

(+)-BUTACLAMOL

Drug Info

[63]

(+/-)-nantenine

Drug Info

[64]

(-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride

Drug Info

[61]

(R)-(+)-coclaurine

Drug Info

[65]

(R)-(-)-10-methyl-11-hydroxyaporphine

Drug Info

[66]

(R)-(-)-11-hydroxy-N-n-propylnoraporphine

Drug Info

[67]

(R)-(-)-2-methoxy-11-hydroxyaporphine

Drug Info

[67]

(R)-(-)-2-methoxy-N-npropylnorapomorphine

Drug Info

[67]

(R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine

Drug Info

[67]

(R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine

Drug Info

[67]

(R)-11-Amino-2-methoxyaporphine

Drug Info

[68]

(R)-2,11-Diaminoaporphine

Drug Info

[68]

(R,S)-homoaromaline hydrochloride

Drug Info

[61]

(S)-BULBOCAPNINE

Drug Info

[69]

(S)APOMORPHINE

Drug Info

[70]

(S,S)-oxandrine hydrochloride

Drug Info

[61]

1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol

Drug Info

[69]

1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol

Drug Info

[69]

1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane

Drug Info

[71]

1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine

Drug Info

[72]

1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol

Drug Info

[73]

1-Aminomethyl-3-phenyl-isochroman-5,6-diol

Drug Info

[55]

1-Aminomethyl-isochroman-5,6-diol

Drug Info

[55]

1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine

Drug Info

[74]

1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine

Drug Info

[74]

1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine

Drug Info

[74]

1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine

Drug Info

[75]

1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine

Drug Info

[38]

1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine

Drug Info

[38]

1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine

Drug Info

[38]

11-Butyryloxy-N-n-propylnoraporphine

Drug Info

[76]

11-Heptanoyloxy-N-n-propylnoraporphine

Drug Info

[76]

11-Hexanoyloxy-N-n-propylnoraporphine

Drug Info

[76]

11-Propionyloxy-N-n-propylnoraporphine

Drug Info

[76]

11-valeryloxynoraporphine

Drug Info

[76]

2-methoxyapomorphine

Drug Info

[71]

2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline

Drug Info

[77]

2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol

Drug Info

[71]

3,8-dibromoboldine

Drug Info

[78]

3-bromoboldine

Drug Info

[78]

3-Chloroboldine

Drug Info

[78]

3-Iodoboldine

Drug Info

[78]

4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one

Drug Info

[79]

4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine

Drug Info

[38]

5-(2-Amino-ethyl)-2-chloro-phenol hydrobromide

Drug Info

[80]

6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol

Drug Info

[81]

6-(2-Amino-ethyl)-biphenyl-2,3-diol

Drug Info

[81]

6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol

Drug Info

[81]

6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol

Drug Info

[81]

9-Aminomethyl-9H-fluorene-2,5,6-triol

Drug Info

[81]

9-Aminomethyl-9H-fluorene-3,4-diol

Drug Info

[81]

BOLDINE

Drug Info

[78]

Etoloxamine

Drug Info

[38]

FALCARINDIOL

Drug Info

[82]

FLUMEZAPINE

Drug Info

[83]

FLUTROLINE

Drug Info

[84]

GLAUCINE

Drug Info

[69]

IBZM

Drug Info

[85]

ISOCLOZAPINE

Drug Info

[86]

ISOLOXAPINE

Drug Info

[87]

MCL-516

Drug Info

[88]

MELOSMINE

Drug Info

[69]

N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide

Drug Info

[89]

N-(4-Propylaminobutyl)-4-biphenylcarboxamide

Drug Info

[89]

NORSTEPHALAGINE

Drug Info

[69]

PUKATEINE

Drug Info

[69]

QUINPIROLE

Drug Info

[90]

Ro-21-7767

Drug Info

[91]

SB-271046

Drug Info

[92]

SCH-12679

Drug Info

[93]

SCH-24518

Drug Info

[95]

SK&F-89626

Drug Info

[96]

STEPHOLIDINE

Drug Info

[99]

TEPA (possesses cytotoxic activity)

Drug Info

[100]

[R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether

Drug Info

[71]

Stimulator

[+] 1 Stimulator drugs

Lu AF28996

Drug Info

[43]

Binder

[+] 1 Binder drugs

BSF-78438

Drug Info

[22]

Cell-based Target Expression Variations

Top

Cell-based Target Expression Variations

Cell-based Target Expression Variations Info

Drug Binding Sites of Target

Top

Ligand Name: Dopamine

Ligand Info

Structure Description

Cryo-EM structure of the dopamine and LY3154207-bound D1 dopamine receptor and mini-Gs complex

PDB:7X2F

Method

Electron microscopy

Resolution

3.00 Å

Mutation

Yes

[102]

PDB Sequence

SVRILTACFL

³⁰

SLLILSTLLG

⁴⁰

NTLVCAAVIR

⁵⁰

FRHLRSKVTN

⁶⁰

FFVISLAVSD

⁷⁰

LLVAVLVMPW

⁸⁰

KAVAEIAGFW

⁹⁰

PFGSFCNIWV

¹⁰⁰

AFDIMCSTAS

¹¹⁰

ILNLCVISVD

¹²⁰

RYWAISSPFR

¹³⁰

YERKMTPKAA

¹⁴⁰

FILISVAWTL

¹⁵⁰

SVLISFIPVQ

¹⁶⁰

LSWHKAKDNC

¹⁸⁶

DSSLSRTYAI

¹⁹⁶

SSSVISFYIP

²⁰⁶

VAIMIVTYTR

²¹⁶

IYRIAQKQIR

²²⁶

RIAALERAAV

²³⁶

HAKNCFKRET

²⁶⁸

KVLKTLSVIM

²⁷⁸

GVFVCCWLPF

²⁸⁸

FILNCILPFC

²⁹⁸

GFCIDSNTFD

³¹⁴

VFVWFGWANS

³²⁴

SLNPIIYAFN

³³⁴

ADFRKAFSTL

³⁴⁴

Residue

Distance (Å)

ASP103

2.521

ILE104

4.225

SER107

3.138

THR108

3.490

LEU190

4.560

TYR194

4.789

SER198

2.166

SER199

4.058

Residue

Distance (Å)

SER202

2.963

TRP285

4.819

PHE288

3.390

PHE289

3.610

ASN292

3.143

VAL317

3.722

TRP321

4.294

Click to View More Binding Site Information of This Target and Ligand Pair

Ligand Name: Apomorphine

Ligand Info

Structure Description

Cryo-EM structure of apomorphine-bound dopamine receptor 1 in complex with Gs protein

PDB:7JVQ

Method

Electron microscopy

Resolution

3.00 Å

Mutation

[103]

PDB Sequence

SVRILTACFL

³⁰

SLLILSTLLG

⁴⁰

NTLVCAAVIR

⁵⁰

FRHLRSKVTN

⁶⁰

FFVISLAVSD

⁷⁰

LLVAVLVMPW

⁸⁰

KAVAEIAGFW

⁹⁰

PFGSFCNIWV

¹⁰⁰

AFDIMCSTAS

¹¹⁰

ILNLCVISVD

¹²⁰

RYWAISSPFR

¹³⁰

YERKMTPKAA

¹⁴⁰

FILISVAWTL

¹⁵⁰

SVLISFIPVQ

¹⁶⁰

LSWHKAKPID

¹⁸⁴

NCDSSLSRTY

¹⁹⁴

AISSSVISFY

²⁰⁴

IPVAIMIVTY

²¹⁴

TRIYRIAQKQ

²²⁴

IRRIAALERA

²³⁴

AVHAKNCQFK

²⁶⁵

RETKVLKTLS

²⁷⁵

VIMGVFVCCW

²⁸⁵

LPFFILNCIL

²⁹⁵

PFCFCIDSNT

³¹²

FDVFVWFGWA

³²²

NSSLNPIIYA

³³²

FNADFRKAFS

³⁴²

TLLGCY

Residue

Distance (Å)

ASP103

3.297

ILE104

4.027

SER107

3.886

THR108

4.026

LEU190

3.577

TYR194

4.955

ALA195

4.922

SER198

2.445

Residue

Distance (Å)

SER199

3.433

SER202

2.974

TRP285

4.100

PHE288

3.562

PHE289

3.618

ASN292

3.074

VAL317

3.673

TRP321

3.349

Click to View More Binding Site Information of This Target with Different Ligands

Different Human System Profiles of Target	Top
Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target. A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020). Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function. Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006). Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database. The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017). Human Similarity Proteins Human Pathway Affiliation Biological Network Descriptors

Different Human System Profiles of Target

Top

Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.

A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020).

Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.

Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006).

Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.

The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017).

Human Similarity Proteins

Human Pathway Affiliation

Biological Network Descriptors

Protein Name	Pfam ID	Percentage of Identity (%)	E value
Olfactory receptor 2T3 (OR2T3)	PF13853	24.390 (60/246)	1.60E-09
Olfactory receptor 2T34 (OR2T34)	PF13853	24.324 (54/222)	4.59E-09
Olfactory receptor 1D2 (OR1D2)	PF13853	26.087 (60/230)	5.11E-08
Olfactory receptor 13J1 (OR13J1)	PF13853	25.654 (49/191)	7.98E-07
Olfactory receptor 2H1 (OR2H1)	PF13853	25.728 (53/206)	8.12E-07
Olfactory receptor 2D2 (OR2D2)	PF13853	26.066 (55/211)	1.02E-06
Olfactory receptor 9A2 (OR9A2)	PF13853	25.743 (52/202)	1.09E-06
Olfactory receptor 1D4 (OR1D4)	PF13853	32.576 (43/132)	2.96E-06
Olfactory receptor 1D5 (OR1D5)	PF13853	32.576 (43/132)	3.43E-06
Olfactory receptor 7A5 (OR7A5)	PF13853	29.167 (42/144)	4.60E-06
Olfactory receptor 1I1 (OR1I1)	PF13853	30.556 (44/144)	5.67E-06
Olfactory receptor 10A6 (OR10A6)	PF13853	23.810 (60/252)	6.69E-06
Olfactory receptor 4K2 (OR4K2)	PF13853	28.571 (36/126)	1.04E-05
Olfactory receptor 2H2 (OR2H2)	PF13853	26.009 (58/223)	1.32E-05
Olfactory receptor 7D2 (OR7D2)	PF13853	28.986 (40/138)	2.62E-05
Olfactory receptor 10G3 (OR10G3)	PF13853	28.682 (37/129)	3.11E-05
Olfactory receptor 2M7 (OR2M7)	PF13853	24.066 (58/241)	4.02E-05
Olfactory receptor 13H1 (OR13H1)	PF13853	25.668 (48/187)	4.07E-05
Olfactory receptor 2AT4 (OR2AT4)	PF13853	31.092 (37/119)	6.66E-05
Olfactory receptor 14J1 (OR14J1)	PF13853	29.286 (41/140)	1.05E-04
Olfactory receptor 7E24 (OR7E24)	PF13853	28.378 (42/148)	1.34E-04
Olfactory receptor 11A1 (OR11A1)	PF13853	30.328 (37/122)	1.41E-04
Olfactory receptor 1A2 (OR1A2)	PF13853	27.350 (32/117)	1.42E-04
Olfactory receptor 6C68 (OR6C68)	PF13853	25.000 (33/132)	1.44E-04
Olfactory receptor 1N2 (OR1N2)	PF13853	28.462 (37/130)	1.52E-04
Olfactory receptor 4D9 (OR4D9)	PF13853	28.261 (39/138)	1.93E-04
Olfactory receptor 2AG2 (OR2AG2)	PF13853	29.126 (30/103)	2.56E-04
Olfactory receptor 1C1 (OR1C1)	PF13853	27.564 (43/156)	2.75E-04
Putative olfactory receptor 7A2 (OR7A2P)	PF13853	29.655 (43/145)	3.34E-04
Olfactory receptor 2A14 (OR2A14)	PF13853	25.225 (56/222)	3.88E-04
Olfactory receptor 10H1 (OR10H1)	PF13853	26.357 (34/129)	4.00E-04
Olfactory receptor 9A4 (OR9A4)	PF13853	27.451 (42/153)	4.10E-04
Olfactory receptor 2M2 (OR2M2)	PF13853	24.121 (48/199)	4.52E-04
Olfactory receptor 2M5 (OR2M5)	PF13853	24.490 (48/196)	4.54E-04
Olfactory receptor 2T10 (OR2T10)	PF13853	24.752 (50/202)	4.78E-04
Olfactory receptor 2T29 (OR2T29)	PF13853	23.711 (46/194)	5.22E-04
Olfactory receptor 2T5 (OR2T5)	PF13853	23.711 (46/194)	5.37E-04
Olfactory receptor 9A1 (OR9A1P)	PF13853	27.094 (55/203)	6.17E-04
Olfactory receptor 4C6 (OR4C6)	PF13853	27.132 (35/129)	6.64E-04
Olfactory receptor 7A10 (OR7A10)	PF13853	28.889 (39/135)	6.70E-04
Olfactory receptor 7A17 (OR7A17)	PF13853	27.737 (38/137)	6.82E-04
Olfactory receptor 10J3 (OR10J3)	PF13853	26.515 (35/132)	7.18E-04
Olfactory receptor 4Q2 (OR4Q2)	PF13853	24.171 (51/211)	7.29E-04
Olfactory receptor 10G7 (OR10G7)	PF13853	28.671 (41/143)	8.05E-04
Olfactory receptor 14I1 (OR14I1)	PF13853	27.692 (36/130)	8.41E-04
Olfactory receptor 6M1 (OR6M1)	PF13853	33.673 (33/98)	1.00E-03
Putative olfactory receptor 14L1 (OR14L1P)	PF13853	24.460 (34/139)	1.00E-03
Olfactory receptor 4Q3 (OR4Q3)	PF13853	26.724 (31/116)	1.00E-03
Olfactory receptor 1E1 (OR1E1)	PF13853	27.559 (35/127)	2.00E-03
Olfactory receptor 2D3 (OR2D3)	PF13853	25.191 (33/131)	2.00E-03
Olfactory receptor 6V1 (OR6V1)	PF13853	26.241 (37/141)	2.00E-03
Olfactory receptor 10H2 (OR10H2)	PF13853	28.829 (32/111)	2.00E-03
Olfactory receptor 2A1/2A42 (OR2A1; OR2A42)	PF13853	25.877 (59/228)	2.00E-03
Olfactory receptor 4K3 (OR4K3)	PF13853	26.866 (36/134)	2.00E-03
Olfactory receptor 11H6 (OR11H6)	PF13853	29.801 (45/151)	2.00E-03
Olfactory receptor 13A1 (OR13A1)	PF13853	29.688 (38/128)	3.00E-03
Olfactory receptor 10H4 (OR10H4)	PF13853	28.829 (32/111)	3.00E-03
Olfactory receptor 2M3 (OR2M3)	PF13853	28.440 (31/109)	3.00E-03
Olfactory receptor 12D3 (OR12D3)	PF13853	31.746 (20/63)	3.00E-03
Olfactory receptor 6C70 (OR6C70)	PF13853	30.508 (36/118)	3.00E-03
Olfactory receptor 2T2 (OR2T2)	PF13853	26.016 (32/123)	4.00E-03
Olfactory receptor 2T35 (OR2T35)	PF13853	26.016 (32/123)	4.00E-03
Olfactory receptor 7G2 (OR7G2)	PF13853	31.034 (36/116)	4.00E-03
Putative olfactory receptor 10D4 (OR10D4P)	PF13853	24.312 (53/218)	4.00E-03
Olfactory receptor 2G6 (OR2G6)	PF13853	25.221 (57/226)	5.00E-03
Click to Show/Hide the Information of Human Similarity Proteins

KEGG Pathway	Pathway ID	Affiliated Target
Calcium signaling pathway	hsa04020	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
cAMP signaling pathway	hsa04024	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
Neuroactive ligand-receptor interaction	hsa04080	Affiliated Target
Class: Environmental Information Processing => Signaling molecules and interaction	Pathway Hierarchy
Gap junction	hsa04540	Affiliated Target
Class: Cellular Processes => Cellular community - eukaryotes	Pathway Hierarchy
Dopaminergic synapse	hsa04728	Affiliated Target
Class: Organismal Systems => Nervous system	Pathway Hierarchy

Degree	2	Degree centrality	2.15E-04	Betweenness centrality	0.00E+00
Closeness centrality	1.73E-01	Radiality	1.28E+01	Clustering coefficient	1.00E+00
Neighborhood connectivity	2.25E+01	Topological coefficient	6.82E-01	Eccentricity	13
Download	Click to Download the Full PPI Network of This Target

Chemical Structure based Activity Landscape of Target

Top

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

Target Poor or Non Binders

Top

Target Poor or Non Binders

Target Poor or Non Binders Info

Target Regulators

Top

Target-regulating microRNAs

Target-regulating microRNAs Info

Target-regulating Transcription Factors

Target-regulating Transcription Factors Info

Target Profiles in Patients

Top

Target Expression
Profile (TEP)

Target Expression Profile Info

Target Affiliated Biological Pathways

Top

KEGG Pathway

[+] 10 KEGG Pathways

Calcium signaling pathway

cAMP signaling pathway

Neuroactive ligand-receptor interaction

Gap junction

Dopaminergic synapse

Parkinson's disease

Cocaine addiction

Amphetamine addiction

Morphine addiction

Alcoholism

Panther Pathway

[+] 1 Panther Pathways

Dopamine receptor mediated signaling pathway

Pathwhiz Pathway

[+] 1 Pathwhiz Pathways

Dopamine Activation of Neurological Reward System

Reactome

[+] 2 Reactome Pathways

Dopamine receptors

G alpha (s) signalling events

WikiPathways

[+] 6 WikiPathways

Hypothetical Network for Drug Addiction

Monoamine GPCRs

GPCRs, Class A Rhodopsin-like

Genes and (Common) Pathways Underlying Drug Addiction

GPCR ligand binding

GPCR downstream signaling

Target-Related Models and Studies

Top

Target Validation

Target Validation Info

References

Top

REF 1

Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.

REF 2

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 985).

REF 3

Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.

REF 4

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 5

REF 6

Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.

REF 7

REF 8

ClinicalTrials.gov (NCT01751802) Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease. U.S. National Institutes of Health.

REF 9

ClinicalTrials.gov (NCT01295372) Safety and Efficacy of Zicronapine in Patients With Schizophrenia. U.S. National Institutes of Health.

REF 10

The SAGE Handbook of Healthcare, Decision Resources Inc. Page(548).

REF 11

Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2015 Jan;40(2):446-53.

REF 12

ClinicalTrials.gov (NCT04291859) Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease. U.S.National Institutes of Health.

REF 13

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006590)

REF 14

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001476)

REF 15

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005232)

REF 16

Decrease of behavioral and biochemical denervation supersensitivity of rat striatum by nigral transplants. Neuroscience. 1991;44(1):75-83.

REF 17

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002584)

REF 18

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004006)

REF 19

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008043)

REF 20

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006052)

REF 21

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008736)

REF 22

The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.

REF 23

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002413)

REF 24

REF 25

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002423)

REF 26

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002637)

REF 27

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006596)

REF 28

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007189)

REF 29

NNC-19-1228 and NNC 22-0031, novel neuroleptics with a "mesolimbic-selective" behavioral profile. Psychopharmacology (Berl). 1997 Jan;129(2):168-78.

REF 30

ORG 10490: A new antipsychotic drug with 5-HT2 and DA antagonistic properties. ScienceDirect, Volume 6, Issue 2, January 1992, Pages 111.

REF 31

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009027)

REF 32

REF 33

The D1 dopamine receptor agonist SKF-38393 stimulates the release of glutamate in the hippocampus. Neuroscience. 1999;94(4):1063-70.

REF 34

REF 35

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004119)

REF 36

Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.

REF 37

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

REF 38

Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.

REF 39

A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.

REF 40

Clinical pipeline report, company report or official report of Lundbeck.

REF 41

Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.

REF 42

trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.

REF 43

Clinical pipeline report, company report or official report of Lundbeck

REF 44

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001476)

REF 45

Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.

REF 46

The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206.

REF 47

Dopamine D1 receptor agonists induce penile erections in rats. Eur J Pharmacol. 2003 Jan 26;460(1):71-4.

REF 48

Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6.

REF 49

Characterization of benzazepine UDP-glucuronosyl-transferases in laboratory animals and man. Xenobiotica. 1995 Jun;25(6):611-22.

REF 50

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008043)

REF 51

PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 1999 May;32(2):93-109.

REF 52

SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm. 1996;103(1-2):17-30.

REF 53

Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Psychopharmacology (Berl). 1999 Feb;142(1):51-60.

REF 54

Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity. J Pharmacol Exp Ther. 1992 Aug;262(2):855-65.

REF 55

(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J Med Chem. 1990 Nov;33(11):2948-50.

REF 56

(+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nucl Med Biol. 2002 Apr;29(3):295-302.

REF 57

BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182-90.

REF 58

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007189)

REF 59

SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity. J Neural Transm. 1996;103(3):261-76.

REF 60

Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys. J Pharmacol Exp Ther. 1993 Nov;267(2):765-75.

REF 61

Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6.

REF 62

Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9.

REF 63

7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists. J Med Chem. 2000 May 18;43(10):2079-81.

REF 64

Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.

REF 65

Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. J Nat Prod. 1998 Jun 26;61(6):709-12.

REF 66

R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30.

REF 67

Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7.

REF 68

Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81.

REF 69

Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81.

REF 70

Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. J Med Chem. 1990 Jun;33(6):1800-5.

REF 71

Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8.

REF 72

Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9.

REF 73

Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands. J Med Chem. 1991 Oct;34(10):2946-53.

REF 74

Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.

REF 75

Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.

REF 76

N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8.

REF 77

Synthesis and evaluation of 1,2,3,4-tetrahydro[1]benzothieno[2,3-h]isoquinolines as dopamine antagonists. J Med Chem. 1981 Sep;24(9):1107-10.

REF 78

Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4.

REF 79

Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.

REF 80

Synthesis and pharmacological characterization of 2-(4-chloro-3-hydroxyphenyl)ethylamine and N,N-dialkyl derivatives as dopamine receptor ligands. J Med Chem. 1992 Nov 13;35(23):4408-14.

REF 81

Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12.

REF 82

Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23.

REF 83

Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.

REF 84

Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43.

REF 85

In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine re... Bioorg Med Chem. 2007 Nov 1;15(21):6819-29.

REF 86

Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53.

REF 87

Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.

REF 88

Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3.

REF 89

Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.

REF 90

Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of he... J Med Chem. 2005 Sep 8;48(18):5771-9.

REF 91

Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine recepto... J Med Chem. 1995 Jan 20;38(2):318-27.

REF 92

Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.

REF 93

Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]ben... J Med Chem. 1998 Nov 5;41(23):4486-91.

REF 94

Dopamine modulates effort-based decision making in rats. Behav Neurosci. 2009 Apr;123(2):242-51.

REF 95

Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. J Med Chem. 1988 Oct;31(10):1941-6.

REF 96

trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem. 1990 Jun;33(6):1756-64.

REF 97

Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol. 1990 Jun 12;188(6):335-47.

REF 98

Identification of G protein-biased agonists that fail to recruit beta-arrestin or promote internalization of the D1 dopamine receptor. ACS Chem Neurosci. 2015 Apr 15;6(4):681-92.

REF 99

Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.

REF 100

N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70.

REF 101

Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature. 1990 Sep 6;347(6288):72-6.

REF 102

Ligand recognition and biased agonism of the D1 dopamine receptor. Nat Commun. 2022 Jun 8;13(1):3186.

REF 103

Structural insights into the human D1 and D2 dopamine receptor signaling complexes. Cell. 2021 Feb 18;184(4):931-942.e18.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN